Other protein fragments and antibody protein molecules are in development as well. For example, the protein component in some new approaches is a highly engineered antibody that is designed specifically for conjugation therapy. Recently, each ADC component type has seen marked innovation. The payload induces apoptosis of the target cell. Upon recognizing that antigen, the ADC is internalized and enzymatically degraded inside cellular lysosomes to generate the active form of the small molecule payload as well as some protein degradation sequences. An ADC in circulation will recognize a specific antigen on the surface of a target cell. The first component is the protein scaffold, normally a monoclonal antibody, which is covalently bound by a linker technology (the second component) to a cytotoxic payload molecule (the third).ĪDCs have a multistep mechanism of action.
The company operates three different facilities, in which it develops and manufactures complex small molecules as well as bioconjugate therapies.ĪDCs are one of the most complex examples of biotherapies approved by the US Food and Drug Administration (FDA) on the market today because they comprise three different components, each of which requires its own separate manufacturing and development process. Juan Cordova, principal scientist in bioconjugation, AbzenaĬordova began his presentation by introducing Abzena as a global network that provides an integrated solution for the development and manufacture of biotherapies, including antibody–drug conjugates (ADCs).
0 kommentar(er)
